Core Viewpoint - The company plans to invest in a biomanufacturing base for APIs and health dietary supplements in Inner Mongolia, with a total investment of 420 million yuan, including approximately 300 million yuan in fixed asset investment [1] Group 1: Project Details - The investment agreement will be signed between the company's subsidiary and the People's Government of Tokto County, Inner Mongolia [1] - The project aims to leverage the geographical advantages and resource endowments of Tokto County [1] Group 2: Strategic Benefits - The establishment of a large-scale, standardized production base will provide a solid foundation for efficient R&D and production activities [1] - Abundant local energy resources are expected to help the company reduce production costs and expand profit margins [1] Group 3: Market Positioning - Upon completion, the project will enhance the company's industrial chain layout and strengthen its market competitiveness [1] - The investment is anticipated to continuously improve the company's core profitability and sustainable development capabilities [1]
拓新药业(301089.SZ)拟4.2亿元投建原料药及健康膳食补充剂生物制造基地建设项目